Gerald Lee, MD
Allergy & Immunology · Atlanta, GANPI 1942474648
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), grants and consulting fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by GSK at 48.4% of the total. Reporting peaked in 2022 at $25,097 and has fallen 88.8% since, to $2,816 in 2025.
Across 23 payments — averaging $2250.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$25K
- Sanofi$20K
- Novartis$7K
- Teva Pharmaceuticals USA, Inc.$122
- Alk-abello, Inc$119
- AstraZeneca$80
- plus $22 from 1 others
What the payments were for
- Consulting fees$6,41312%
- Speaking & faculty fees$29,00056%
- Grants$15,50030%
- Food & beverage$8372%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $25,027 |
| Sanofi | 8 | $19,590 |
| Novartis | 7 | $6,790 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Alk-abello, Inc | 1 | $119 |
| AstraZeneca | 2 | $80 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Albuterol Sulfate$122
- Odactra$119
How this compares
$51,750 in reported general payments places this provider in the 85th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 36 | $131,742 |
| Dupixent SyringeDupilumab | 13 | $46,305 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $18,528 |
| DuleraMometasone/Formoterol | 32 | $13,555 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,655 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $8,399 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,189 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $5,381 |
| Epinephrine | 17 | $3,527 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,946 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,731 |
| Azelastine Hcl | 83 | $2,376 |
| Ipratropium Bromide | 52 | $1,370 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,365 |
| Fluticasone Propionate | 110 | $1,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $25,027 | $31,09852 claims |
| AstraZenecaSymbicort | $80 | $8,39938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Atlanta
- Deborah BirxAtlanta$470K
- Paul RabinowitzAtlanta$57K
- Luqman SeiduAtlanta$32K
- Alan ReddingAtlanta$23K
- David ReddingAtlanta$22K
- Merin KalangaraAtlanta$19K
- Glen NadelAtlanta$12K
- Keith LenchnerAtlanta$11K
- Santhosh Kumar Bangalore Vasantha KumarAtlanta$11K
- David TannerAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.